Thoroughbred Financial Services LLC Purchases New Position in Guardant Health, Inc. $GH

Thoroughbred Financial Services LLC purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 6,354 shares of the company’s stock, valued at approximately $648,000.

Several other institutional investors have also bought and sold shares of the stock. Seven Grand Managers LLC acquired a new stake in Guardant Health in the 4th quarter valued at $4,086,000. Geode Capital Management LLC raised its position in Guardant Health by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after purchasing an additional 277,001 shares during the last quarter. Clearstead Advisors LLC boosted its stake in Guardant Health by 2,277.1% in the fourth quarter. Clearstead Advisors LLC now owns 1,141 shares of the company’s stock worth $117,000 after purchasing an additional 1,093 shares in the last quarter. Legal & General Group Plc boosted its stake in Guardant Health by 3.4% in the fourth quarter. Legal & General Group Plc now owns 156,779 shares of the company’s stock worth $16,013,000 after purchasing an additional 5,174 shares in the last quarter. Finally, Lisanti Capital Growth LLC acquired a new position in Guardant Health in the fourth quarter worth $3,949,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the topic of a number of recent analyst reports. Raymond James Financial reissued an “outperform” rating and issued a $129.00 price objective on shares of Guardant Health in a research note on Monday, February 23rd. Stifel Nicolaus boosted their price objective on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Leerink Partners boosted their price objective on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. BTIG Research set a $160.00 price objective on Guardant Health and gave the stock a “buy” rating in a research note on Wednesday. Finally, Guggenheim lowered Guardant Health from a “buy” rating to a “buy” rating in a research note on Thursday. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $129.79.

Guardant Health Stock Down 2.6%

GH stock opened at $129.69 on Friday. The company has a market cap of $17.20 billion, a P/E ratio of -38.26 and a beta of 1.48. Guardant Health, Inc. has a twelve month low of $38.03 and a twelve month high of $133.97. The business has a fifty day moving average of $95.08 and a 200-day moving average of $99.94.

Insider Activity at Guardant Health

In related news, insider John G. Saia sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $125.08, for a total value of $1,250,800.00. Following the completion of the sale, the insider owned 35,950 shares in the company, valued at approximately $4,496,626. This represents a 21.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Medina Manuel Hidalgo sold 1,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $130.06, for a total value of $130,060.00. Following the completion of the sale, the director owned 639 shares of the company’s stock, valued at $83,108.34. This represents a 61.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 332,244 shares of company stock valued at $36,156,026 over the last quarter. 5.60% of the stock is currently owned by corporate insiders.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.